Woodline Partners’s Esperion Therapeutics ESPR Stock Holding History

Woodline Partners’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$401K	Hold	127,028	–	–	﹤0.01%	982
2026 Q1	$348K	Sell	127,028 -2	-0%	-$6	﹤0.01%	991
2025 Q4	$470K	Sell	127,030 -255,057	-67%	-$824K	﹤0.01%	909
2025 Q3	$1.01M	Sell	382,087 -1,121,667	-75%	-$2.17M	﹤0.01%	802
2025 Q2	$1.48M	Hold	1,503,754	–	–	0.01%	761
2025 Q1	$2.17M	Buy	1,503,754 +8	+0%	+$15	0.01%	651
2024 Q4	$3.31M	Sell	1,503,746 -740,614	-33%	-$1.73M	0.02%	568
2024 Q3	$3.7M	Sell	2,244,360 -2,805,448	-56%	-$5.66M	0.03%	426
2024 Q2	$11.2M	Sell	5,049,808 -2,872,421	-36%	-$6.76M	0.11%	235
2024 Q1	$21.2M	Buy	7,922,229 +7,631,847	+2,628%	+$18.5M	0.2%	163
2023 Q4	$868K	Buy	+290,382	New	+$377K	0.01%	411
2023 Q2	–	Sell	-423,814	Closed	-$674K	–	674
2023 Q1	$674K	Hold	423,814	–	–	0.01%	506
2022 Q4	$2.64M	Sell	423,814 -771,891	-65%	-$5.52M	0.04%	436
2022 Q3	$8.01M	Buy	1,195,705 +351,070	+42%	+$2.41M	0.11%	226
2022 Q2	$5.37M	Buy	+844,635	New	+$4.79M	0.08%	250

Other funds holding ESPR

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return

OBAM

ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Woodline Partners's ESPR Position: Q2 2026 in Review

Woodline Partners held its Esperion Therapeutics (ESPR) position steady in Q2 2026 at 127,028 shares worth $401K. The position accounts for ﹤0.01% of the portfolio, ranked #982.

Woodline Partners first reported a position in ESPR in Q2 2022 and has held it in 15 quarters since. The position peaked at $21.2M in Q1 2024. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

Woodline Partners held 127,028 shares of Esperion Therapeutics worth $401K as of Q2 2026.
Woodline Partners left its Esperion Therapeutics share count unchanged in Q2 2026.
Esperion Therapeutics made up ﹤0.01% of Woodline Partners's portfolio in Q2 2026, its #982 holding.
Woodline Partners first reported a position in Esperion Therapeutics in Q2 2022 and has held it in 15 quarters since.
Woodline Partners's Esperion Therapeutics position peaked at $21.2M in Q1 2024.
191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.